乳腺癌核素分子显像的临床研究进展

关晏星; 关晏星

[1]

Buck AK,Schirmeister H,Mattfeldt T,et al.Biological characterization of breast cancer by means of PET.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S80-S87.

[2]

Wu D,Gambhir SS.Positron emission tomography in diagnosis and management of invasive breast cancer:.Current status and future perspectives.Clin Breast Cancer,2003,4(Suppl 1):S55-S63.

[3]

王玲,张炽敏.乳腺肿瘤的影像学诊断进展.国外医学·放射医学核医学分册,2005,29(2):93-96.

[4]

Kumar A.Fluorodeoxyglucose-PET in the management of breast cancer.Radiol Clin North Am,2004,42(6):1113-1122.

[5]

Andrew Q,Sanjiv S G.FDG-PET and beyond:Molecular breast cancer imaging.J Clin Oncol,2005,23(8):1664-1673.

[6]

Wang Y,Yu J,Liu J,et al.PET-CT in the diagnosis of both primary breast cancer and axillary lymph node metastasis:initial experience.Int J Radiat Oncol Biol Phys,2003,57(Suppl 1):362-363.

[7]

Bellon JR,Livingston RB,Eubank WIB.Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer(LABC).Am J Clin Oncol,2004,27(4):407-410.

[8]

Eubank WB,Mankoff DA,Takasugi J,et al.18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.J Clin Oncol,2001,19(12):3516-3523.

[9]

Lin WY,Tsai SC,Cheng KY,et al.Fluroine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer-Taiwanese experiences.Cancer Invest,2002,20(5-6):725-729.

[10]

Pecking Ap,Mechelany-Corone C,Bertrand-kermorgant F,et al.Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomogaphy.Clin Breast Cancer,2001,2(3):229-234.

[11]

Pelosi E,Messa C,Sironi S,et al.Value of integrated PET/CT for lesion localization in cancer patients:A comparative study.Eur J Nucl Med Mol Imaging,2004,31(6):932-939.

[12]

Uematsu T,Yuen S,Yukisawa S,et al.Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer.Am J Roentgenol,2005,184(4):1266-1273.

[13]

Krak NC,Hoekstra OS,Lammertsma AA.Measuring response to chemotherapy in locally advanced breast cancer:methodological considerations.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S103-S111.

[14]

Schelling M,Avril N,Nahrig J,et al.Positron emission tomography using[(18)F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.J Clin Oncol,2000,18(18):1689-1695.

[15]

Mortimer JE,Dehdashti F,Siegel BA,et al.Metabolic flare:indicator of hormone responsiveness in advanced breast cancer.J Clin Oncol,2001,19(11):2797-2803.

[16]

Smyczek-Gargya B,Fersis N,Dittmann H,et al.PET with [18F]fluorothymidine for imaging of primary breast cancer:A pilot study.Eur J Nucl Med Mol Imaging,2004,31(5):720-724.

[17]

Pio BS,Park CK,Silverman DH.PET with fluoro-L-thymididne allows early prediction of breast cancer response to chemotherapy.J Nucl Med,2003,44(1):76-77.

[18]

Takamura Y,Miyoshi Y,Taguchi T,et al.Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients.Cancer,2001,92(2):232-239.

[19]

Fuster D,Munoz M,Pavia J,et al.Quantified ^99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients:factors that influence the level of ^99mTc-MIBI uptake.Nucl Med Commun,2002,23(1):31-38.

[20]

Kim R,Osaki A,Hirai T,et al.Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer.Breast Cancer,2002,9(3):240-247.

[21]

Aloj L,Zannetti A,Caraco C,et al.Bcl-2 overexpression prevents ^99mTc-MIBI uptake in breast cancer cell lines.Eur J Nucl Med Mol Imaging,2004,31(4):521-710.

[22]

Del Vecchio S,Salvatore M.^99mTc-MIBI in the evaluation of breast cancer biology.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S88-S96.

[23]

Zhoanglin Liu,Stevenson GD,Barrett HH,et al.Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using ^99mTc-labeled sestamibi and tetrofosmin.Nucl Med Biol,2005,32(6):573-583.

[24]

Britz-Cunning ham,SH,James-Adelstein S.Molecular targeting with radionuclides:state of the science.J Nucl Med,2003,44(12):1945-1961.

[25]

Bennink RJ,van Tienhoven G,Rijks LJ,et al.In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer.J Nucl Med,2004,45(1):1-7.

[26]

Behr TM,Behe M,Angerstein C,et al.Does pretherapeutic immunoscintigraphy allow for diagnostic predictions with respect to the toxicity and therapeutic efficacy of cold immunotherapy with trastuzumab (Herceptin)?.J Nucl Med,2000,41(1):73.

[27]

吴浩荣,吴锦昌.Baum R. ^99mTc标记抗粘蛋白McAb乳腺癌放射免疫显像的临床研究.中华核医学杂志,2000,20(2):75-77.

[28]

Murakami Y,Takamatsu H,Taki J,et al.¹⁸F-labelled annexin V:a PET tracer for apoptosis imaging.Eur J Nucl Med Mol Imaging,2004,31(4):469-474.